Climb Bio (NASDAQ:CLYM) Upgraded to “Moderate Buy” at Royal Bank Of Canada

Posted by George Bondi on Aug 4th, 2026

Royal Bank Of Canada upgraded shares of Climb Bio (NASDAQ:CLYM – Free Report) to a moderate buy rating in a report released on Monday, MarketBeat.com reports. They currently have $23.00 price target on the stock.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Climb Bio from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Mizuho assumed coverage on shares of Climb Bio in a report on Wednesday, April 15th. They issued an “outperform” rating and a $18.00 price objective for the company. BTIG Research raised their target price on shares of Climb Bio from $19.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a research report on Friday, July 17th. Finally, Guggenheim started coverage on Climb Bio in a report on Monday, June 8th. They issued a “buy” rating and a $35.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $22.08.

Check Out Our Latest Report on Climb Bio

Climb Bio Price Performance

Shares of Climb Bio stock opened at $11.81 on Monday. The stock has a market capitalization of $676.24 million, a P/E ratio of -15.14 and a beta of 0.08. The business has a 50 day simple moving average of $12.22 and a two-hundred day simple moving average of $9.07. Climb Bio has a 12 month low of $1.54 and a 12 month high of $14.41.

Climb Bio (NASDAQ:CLYM – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.06. As a group, research analysts anticipate that Climb Bio will post -0.87 EPS for the current fiscal year.

Institutional Trading of Climb Bio

Several institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC purchased a new position in Climb Bio in the first quarter worth approximately $27,000. Qube Research & Technologies Ltd acquired a new stake in Climb Bio during the second quarter worth $43,000. Virtu Financial LLC purchased a new stake in Climb Bio in the fourth quarter valued at $43,000. Blair William & Co. IL purchased a new stake in Climb Bio in the fourth quarter valued at $44,000. Finally, Marshall Wace LLP acquired a new position in shares of Climb Bio in the 2nd quarter valued at $46,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Climb Bio Company Profile

(Get Free Report)

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.